NCT00921115View on ClinicalTrials.gov

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

April 30, 2015

Study Completion Date

March 20, 2023

Conditions
Invasive Breast Cancer
Interventions
DRUG

Fulvestrant

Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.

DRUG

Anastrazole

Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Kansas Medical Center

OTHER